Evidence map›Paper›PMID 41874002›Full record

ArticleJCI insight2026

Repurposing T-type calcium channel blocker lomerizine as a therapeutic strategy for glioblastoma.

Toshiya Ichinose, Sho Tamai, Nozomi Hirai, Takashi Maejima, Kosuke Nambu, Hemragul Sabit, Shingo Tanaka, Masashi Kinoshita, Masahiko Kobayashi, Michihiro Mieda and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Toshiya IchinoseDepartment of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Ishikawa, Japan.
Sho TamaiDepartment of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Ishikawa, Japan.
Nozomi HiraiDepartment of Neurosurgery, Toho University Ohashi Medical Center, Tokyo, Japan.
Takashi MaejimaDepartment of Integrative Neurophysiology, Graduate School of Medical Sciences, and.
Kosuke NambuDepartment of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Ishikawa, Japan.
Hemragul SabitDepartment of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Ishikawa, Japan.
Shingo TanakaDepartment of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Ishikawa, Japan.
Masashi KinoshitaDepartment of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Ishikawa, Japan.
Masahiko KobayashiDivision of Molecular Genetics, Cancer Research Institute, Kanazawa University, Ishikawa, Japan.
Michihiro MiedaDepartment of Integrative Neurophysiology, Graduate School of Medical Sciences, and.
Atsushi HiraoDivision of Molecular Genetics, Cancer Research Institute, Kanazawa University, Ishikawa, Japan.
Mitsutoshi NakadaDepartment of Neurosurgery, Graduate School of Medical Science, Kanazawa University, Ishikawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is the most malignant primary brain tumor. The presence of glioma stem/initiating cells (GICs) is known to cause strong treatment resistance; therefore, GICs are a major target for GBM therapy, although there are no therapies targeting GICs clinically. To identify novel treatments for GBMs, we performed drug repurposing screening using GICs and identified the T-type calcium channel blocker lomerizine - a migraine prophylactic drug. Lomerizine inhibited proliferation, migration, invasion, and cell cycle progression and induced apoptosis in GICs and differentiated glioma cells. Lomerizine had antitumor effects by inactivating STAT3 in all cell lines. Furthermore, lomerizine also dephosphorylated AKT and ERK only in GICs and had strong tumor-suppressive ability. Lomerizine also reduced tumor volume and prolonged overall survival in vivo. Based on our data from in vitro and in vivo experiments, lomerizine has potential as a GBM therapeutic agent targeting both GICs and differentiated glioma cells and could benefit GBM patients.

Indexed as

Brain NeoplasmsCalcium Channel BlockersDrug RepositioningGlioblastomaAnimalsApoptosisCalcium Channels, T-TypeCell Line, TumorCell MovementCell ProliferationFemaleHumansMiceNeoplastic Stem CellsPiperazinesSTAT3 Transcription FactorCalcium Channel BlockersCalcium Channels, T-TypelomerizinePiperazinesSTAT3 Transcription FactorBrain cancerCell biologyOncology

Identifiers

PMID41874002
PMCPMC13232010

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.